Respiratory · VITD-RESP-02 · v2
Several large, well-designed trials gave hospitalised COVID-19 patients vitamin D or a placebo and then looked at outcomes that matter to patients, such as how long they stayed in hospital, whether they needed intensive care or a ventilator, and whether they died. The biggest of these trials [2], [13], [14] found no difference between vitamin D and placebo, and a very large prevention trial [8] found no reduction in infection. The results that looked encouraging came from much smaller or weaker studies: a 50-patient pilot [12], a trial comparing two doses with no placebo [7], a study measuring virus clearance rather than recovery [4], a survival signal that appeared at two weeks but had vanished by four [11], and a look-back at hospital records [20]. Because the strongest evidence points to no benefit while the encouraging signals sit in the weakest designs, the panel judged the broad claim to be poorly supported. It stopped short of calling the claim refuted because fragile hints of benefit persist in people who started out vitamin D deficient and on softer measures.
The three largest placebo-controlled treatment trials are null on hard endpoints: [2] (N=237) found median length of stay of 7.0 days in both arms (hazard ratio 1.07) with no difference in mortality, ICU admission or ventilation; [13] (N=543) found length of stay, ICU admission and death unchanged; and [14] (N=218) found no effect on respiratory worsening, length of stay, ICU admission or mortality. The large prevention trial [8] (N=6200) found no reduction in acute respiratory infection or COVID-19. Supportive signals are confined to weaker designs: a placebo-controlled 50-patient pilot reporting length of stay of 4 versus 8 days [12], a surrogate viral-clearance endpoint of 62.5% versus 20.8% RNA-negative [4], faster cough and taste recovery in a 5000-versus-1000 IU dose comparison [7], a 14-day mortality signal that was not sustained at 28 days [11], and a retrospective cohort [20]. A calcifediol trial [9] improved the neutrophil-to-lymphocyte ratio but its clinical endpoints were not statistically significant. The contested point: The division is between endpoint hardness and design quality: positive results appear on surrogate or soft endpoints ([4] viral clearance, [9] neutrophil-to-lymphocyte ratio, [7] symptom recovery) and in small, non-placebo or observational designs, while every large placebo-controlled trial on mortality, length of stay, ICU and ventilation is null ([2], [13], [14]). Whether any benefit is real and concentrated in vitamin D–deficient subgroups, or is an artefact of underpowered and weaker trials, is the unresolved point.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin D, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The three largest placebo-controlled treatment RCTs ([2] N=237, [13] N=543, [14] N=218) are uniformly null on hard clinical outcomes (LOS, ICU, ventilation, respiratory worsening, mortality). The affirmative case rests on markedly smaller and weaker trials.
Several 'positive' results are on surrogate rather than clinical endpoints: viral RNA clearance [4] and neutrophil-to-lymphocyte ratio [9] (whose own clinical endpoints were non-significant). Surrogate improvement does not establish improved clinical outcomes.
Where it remains uncertain. The encouraging results rest on a 50-patient pilot [12], a surrogate viral-clearance endpoint [4], a placebo-free dose comparison [7] and a day-14-only mortality signal that disappeared by day 28 [11].
Aleatory
The positive effects sit in small samples ([12] N=50, [4] N=40) where chance alone can produce large apparent effects not reproduced in the larger trials.
Epistemic
Trials differ in baseline vitamin D status ([4] and [12] enrolled deficient patients; [8] a mixed population), so whether benefit is confined to deficiency is not resolved by the corpus.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest-to-date placebo-controlled hospitalized RCT (N=237): null on the primary clinical outcome — refutes the claim for moderate-severe disease.
“Among hospitalized patients with COVID-19, a single high dose of vitamin D3, compared with placebo, did not significantly reduce hospital length of stay. The findings do not support the use of a high dose of vitamin D3 for treatment of moderate to severe COVID-19.”
Panel auditInternal validity: high · scope of inference: Hospitalized patients with moderate-to-severe COVID-19 given a single high bolus dose.Key limitations: single-bolus late dosing · mean baseline 25(OH)D only mildly low
Positive on a surrogate (viral clearance) in mild disease (N=40), not a hard clinical outcome.
“10 (62.5%) participants in the intervention group and 5 (20.8%) participants in the control arm (p<0.018) became SARS-CoV-2 RNA negative.”
Panel auditInternal validity: low · scope of inference: Asymptomatic or mildly symptomatic vitamin D-deficient SARS-CoV-2-positive individuals.Key limitations: tiny sample · virological/biomarker endpoints not clinical outcomes · excluded severe disease
Faster symptom recovery, but comparator is a lower active dose (1000 IU), not placebo.
“the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039)”
Panel auditInternal validity: medium · scope of inference: Hospitalized mild-to-moderate COVID-19 patients with sub-optimal vitamin D status.Key limitations: no placebo arm · small sample · selected secondary symptom endpoints significant
Clinical outcomes showed only a non-significant favourable trend; only the neutrophil-to-lymphocyte ratio marker changed significantly.
Panel auditInternal validity: medium · scope of inference: Hospitalized vitamin D-deficient/insufficient COVID-19 patients.Key limitations: underpowered pilot · clinical benefit only a non-significant trend · primary signal on a surrogate marker
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
High-quality large placebo-controlled trials on hard outcomes are null, while the supportive evidence is small, surrogate-based, non-placebo-controlled or observational, so the claim as worded is weakly supported.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Deficiency-restricted treatment RCT on hard outcomes. Positive signals cluster in deficient patients ([4], [12]) while large trials enrolled broader populations ([2], [8]); the claim cannot be resolved without testing the deficient subgroup directly. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large, double-blind, placebo-controlled treatment RCT enrolling only baseline-deficient hospitalised patients, powered for mortality, ICU admission and length of stay.
Open question: Does vitamin D supplementation improve hard clinical outcomes specifically in baseline vitamin D–deficient hospitalised COVID-19 patients? Why it is still open: The large null trials ([2], [13], [14]) did not restrict to deficiency, while the positive signals in [4] and [12] came from deficient patients, leaving the subgroup question unresolved.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19